Hospital Antibiotics Pipeline Analysis: Big Pharma's Retreat Creates Opportunities for Biotech

Table of Contents

Executive Summary

• Which companies are the major players in the hospital antibiotics market?
• Which companies are the emerging players developing hospital antibiotics?
• What is the commercial outlook for the hospital antibiotics market?

Chapter 1. Introduction

• Overview
• Scope of the Report

Chapter 2. Select Hospital-Based Infections

• Pathogens Associated with Hospital-Based Infections
• Risk Factors Associated with Hospital-Based Infection
  • Sources of Infection
    • Medical Devices
    • Intensive Care Units
  • Susceptible Populations
    • Neonates and the Elderly
    • Immunocompromised and Critically Ill Patients
• Hospital-Based Infections
  • Urinary Tract Infections
  • Bloodstream Infections
  • Hospital-Acquired Pneumonia
  • Community-Acquired Pneumonia
  • Surgical Site Infections
  • Skin and Soft Tissue Infections
    • Cellulitis
    • Abscesses
    • Necrotizing Fasciitis and Gangrene

Chapter 3. Therapies for Hospital-Based Infections

• Overview
• Cell-Wall Synthesis Inhibitors
  • Beta-Lactams
    • Penicillins
    • Cephalosporins
    • Carbapenems
    • Monobactams
  • Glycopeptides and Lipopeptides
• DNA Synthesis Inhibitors
  • Fluoroquinolones
  • Folic Acid and Thymine Synthesis Inhibitors
• Protein Synthesis Inhibitors
  • Aminoglycosides
  • Tetracyclines and Glycylcyclines
  • Oxazolidinones
  • Macrolides, Lincosamides, and Streptogramins
    • Macrolides
    • Lincosamides
    • Streptogramins
• Emerging Drug Classes
  • Peptidyl Deformylase Inhibitors
  • Monoclonal Antibodies
  • Peptide Antibiotics
  • Vaccines

Chapter 4. Pipeline Analysis of Key Companies in the Hospital Antibiotics Market

• Overview
• Aerogen
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• Arpida
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• AstraZeneca
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• Basilea Pharmaceutica
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• Bayer
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• Bristol-Myers Squibb
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• Cubist Pharmaceuticals
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• Enanta Pharmaceuticals
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• GlaxoSmithKline
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• InterMune
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• Johnson & Johnson
  • Select Alliances in the Hospital Antibiotics Area
  • Financial Details
• Merck
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Novartis
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Novexel
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Oscient Pharmaceuticals
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Peninsula Pharmaceuticals
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Pfizer
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Roche
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Sanofi-Aventis
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Schering-Plough
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Theravance
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Vicuron Pharmaceuticals
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details
• Wyeth
  • Select Alliances in the Hospital Antibiotics Area.
  • Financial Details

Chapter 5. Outlook for Hospital Antibiotics Market

Appendix. Bibliography